Bessor Pharma

Bessor Pharma is a privately held, pre-revenue biotech company leveraging a dual-strategy of therapeutic and platform development. Its core focus is on advancing novel small molecule programs in immuno-oncology and inflammation, while simultaneously building a proprietary biomimetic chemical synthesis platform to access a new class of natural product-like compounds. The company's model involves de-risking projects internally before seeking partnerships, supported by a leadership team with deep industry experience in drug development, chemistry, and business strategy.

Novel biomimetic chemical synthesis platform designed to access an untapped class of natural products for drug discovery and development.

Bessor operates in highly competitive arenas. In immuno-oncology, it competes with large pharma and numerous biotechs developing novel checkpoint modulators and targeted therapies. The inflammation space for acute injury is also crowded with companies exploring anti-inflammatory and cytoprotective agents. Its synthesis platform would compete with other drug discovery technology companies and CROs offering chemistry services.